which is a component of the nursing management of the client with new variant creutzfeldt-jakob disease (vcjd)?

1 answer:

3 0

Providing palliative care is a component of the nursing management of the client with new variant Creutzfeldt-Jakob disease.

<h3>How do u get Creutzfeldt-Jakob disease?</h3>

Hereditary CJD accounts for 15 percent of cases in the US. When CJD is acquired, brain or central nervous tissue is exposed, typically during specific medical procedures. There is no proof that CJD can spread through informal contact with an infected person.

<h3>Can Creutzfeldt-Jakob disease be beaten?</h3>

The condition usually results in death within 8 months. Variant CJD patients deteriorate more gradually, but they still die from the disease. Few people live for more than a year or two. Typically, infections, heart problems, or respiratory distress are the causes of mortality.

To know more about Creutzfeldt-jakob disease visit:

brainly.com/question/28989974

#SPJ4

You might be interested in

Organs form different systems that carry out distinct body processes.

Brilliant_brown [7]

Cardiovascular system. It’s main function is to pump blood.
Hope it helps. Please mark as brainliest

5 0

3 years ago

Too much moisture in barns or dry lots can lead to the

OlgaM077 [116]

Around feeders and waterers

7 0

3 years ago

Tuberculosis is a serious bacteria infection. If you become infected with tuberculosis you will?

Mashcka [7]

Cough a lot and have to go to the doctor because if it’s not treated it can turn into pneumonia

8 0

4 years ago

venetoclax plus hypomethylating agent effective in newly diagnosed acute myeloid leukemia, safe in outpatient setting

ruslelena [56]

According to a study, venetoclax plus hypomethylating agent is effective in newly diagnosed acute myeloid leukemia, and safe in an outpatient setting. So the statement is true.

<h3>What is venetoclax?</h3>

Venetoclax is either used alone or in combination with another drug called obinutuzumab or rituximab. This is used for the treatment of certain types of chronic lymphocytic leukemia. It is a type of cancer that develops in white blood cells. It is also used for certain types of small lymphocytic lymphoma, which is a type of cancer that develops in the lymph nodes.

It can also be used in combination with either azacitidine, decitabine, or cytarabine. This is done as the initial treatment for acute myeloid leukemia, which is a type of cancer that begins in the white blood cells in people who are 75 years or older. It can also develop in adults having medical conditions that prevent them from being treated with any other treatment than chemotherapy medications.

The class of medications from which Venetoclax belongs is called B-cell lymphoma-2 inhibitors. These medicines work by blocking the action of a particular protein in the body that promotes cancer cells' survival. This helps in killing cancer cells.

Therefore, the statement is true.